Dr Reddy's-Nestlé India JV launches drug to address nutrition gaps and preserving muscle health among diabetic, obesity patients on GLP-1 therapy
Dr. Reddy's and Nestlé Health Science, a joint venture, have launched Celevida GLP+, a nutritional supplement for individuals undergoing GLP-1/GIP therapy for type 2 diabetes and obesity. This product aims to address nutrition gaps and preserve muscle mass, particularly important as GLP-1 drug patents expire and generics become available. Celevida GLP+ is scientifically formulated with fast-absorbing whey protein isolate and essential nutrients, co-created with endocrinologists and diabetologists to complement pharmacological treatments.
APR 29·NDTV Profit→
Dr Reddy's Wins Canada Approval For Generic Ozempic, Price War Looms To Make GLP-1 Affordable
Canada has approved its first generic versions of the diabetes drug Ozempic, developed by Dr Reddy's Laboratories. This approval, following the expiry of Novo Nordisk's patent in Canada, is expected to significantly reduce treatment costs and intensify competition in the global GLP-1 therapy market.
MAR 27·Stock Titan→
New DR REDDYS (NYSE: RDY) director reports insider status with Form 3 filing
DR REDDYS LABORATORIES LTD director Arun Madhavan Kumar has filed an initial Form 3, establishing his status as a reporting insider. This filing, dated March 27, 2026, is a mandatory statement of beneficial ownership and does not indicate any transactions or holdings. It serves to set a baseline for future ownership disclosures by Mr. Kumar.
